Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07517068
EARLY_PHASE1

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

Sponsor: University of California, Riverside

View on ClinicalTrials.gov

Summary

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Official title: The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude: a Randomized Cross-over Controlled Trial

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

19

Start Date

2025-09-17

Completion Date

2026-12-15

Last Updated

2026-04-08

Healthy Volunteers

Yes

Interventions

DRUG

ACETAZOLAMIDE oral capsule

Acetazolamide is administered orally in pill form at a 125 mg dose taken twice per day (morning and evening) starting 2 days before ascent to high altitude and each day while at high altitude.

DEVICE

Placebo Arm

Not utilization of Acetazolamide (ACZ) oxygenation (SpO2) or any other supportive measurement will be used with this group.

Locations (1)

University of California, Riverside

Riverside, California, United States